 Kole DeGolier
Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 3 | 2025 | 342 | 1.540 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2025 | 21 | 0.920 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 923 | 0.680 |
Why?
| | Immunotherapy | 3 | 2020 | 667 | 0.330 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3551 | 0.290 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 735 | 0.250 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 936 | 0.230 |
Why?
| | Antigens, CD19 | 1 | 2025 | 128 | 0.220 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1997 | 0.220 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 45 | 0.220 |
Why?
| | T-Box Domain Proteins | 1 | 2025 | 106 | 0.210 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 224 | 0.210 |
Why?
| | Protein Domains | 1 | 2025 | 311 | 0.200 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 297 | 0.180 |
Why?
| | Immunologic Memory | 1 | 2025 | 368 | 0.180 |
Why?
| | Leukemia | 1 | 2025 | 246 | 0.180 |
Why?
| | Mice | 6 | 2025 | 18357 | 0.180 |
Why?
| | Genetic Engineering | 1 | 2020 | 88 | 0.160 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 68 | 0.150 |
Why?
| | Protein Binding | 1 | 2025 | 2240 | 0.150 |
Why?
| | Brain Stem Neoplasms | 1 | 2019 | 87 | 0.130 |
Why?
| | Orphan Nuclear Receptors | 1 | 2017 | 14 | 0.130 |
Why?
| | Retinitis Pigmentosa | 1 | 2017 | 20 | 0.130 |
Why?
| | Animals | 6 | 2025 | 38100 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2019 | 274 | 0.130 |
Why?
| | Glioblastoma | 1 | 2020 | 354 | 0.120 |
Why?
| | Transcription Factors | 1 | 2023 | 1736 | 0.110 |
Why?
| | Killer Cells, Natural | 1 | 2018 | 481 | 0.100 |
Why?
| | Macrophages | 1 | 2020 | 1507 | 0.090 |
Why?
| | Signal Transduction | 1 | 2025 | 5223 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1329 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2020 | 1331 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2601 | 0.070 |
Why?
| | Humans | 7 | 2025 | 145750 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2913 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4569 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 420 | 0.040 |
Why?
| | Cricetulus | 1 | 2020 | 118 | 0.040 |
Why?
| | CHO Cells | 1 | 2020 | 169 | 0.040 |
Why?
| | Chromatin | 1 | 2023 | 553 | 0.040 |
Why?
| | Transfection | 1 | 2020 | 927 | 0.030 |
Why?
| | 4-1BB Ligand | 1 | 2018 | 7 | 0.030 |
Why?
| | K562 Cells | 1 | 2018 | 92 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2018 | 95 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2018 | 440 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 2051 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2094 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1777 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4329 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3170 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5428 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 4090 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6464 | 0.020 |
Why?
| | Infant | 1 | 2019 | 10089 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11866 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11793 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 14250 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22569 | 0.010 |
Why?
| | Child | 1 | 2019 | 22738 | 0.010 |
Why?
| | Adult | 1 | 2019 | 40867 | 0.010 |
Why?
| | Male | 1 | 2019 | 72992 | 0.010 |
Why?
| | Female | 1 | 2019 | 79025 | 0.000 |
Why?
|
|
DeGolier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|